Using nasal drug delivery to improve treatment for neurological disorders
Official title: Integration of Drug Release and Permeability with Systems Data Relevant to PBPK Model of Nose-to-Brain Axis and Verification Using Clinical Data
Funded at University of Manchester · NIH-10701846 · Data updated 2026-11-12
This study is looking at a new way to help medicines delivered through the nose reach the brain better, which could be really helpful for people with tough brain conditions, making sure these medicines are safe and work well for them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Manchester NIH-funded |
| Lab location | 1 site (Manchester, United Kingdom) |
| Project start | September 15, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $264,446 |
| NIH project number | 5U01FD007657-02 |
| Project ID | NIH-10701846 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with neurological disorders who may benefit from improved drug delivery methods.
✕Less likely to help
Patients with conditions that do not involve the central nervous system may not receive benefit from this research.
What this research studies
This research focuses on developing a new model for how drugs delivered through the nose can effectively reach the brain, bypassing barriers that typically limit drug effectiveness for neurological conditions. By creating a physiologically-based pharmacokinetic (PBPK) model, the project aims to understand how drugs are absorbed and distributed in the body after intranasal delivery. This approach will help ensure that generic drugs are safe and effective for patients, particularly those with challenging neurological disorders.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for neurological disorders by improving drug delivery to the brain.
How similar studies have gone: While the approach of using intranasal delivery for neurological disorders is being explored, this specific PBPK model development is novel and has not been extensively tested in prior research.
Where this research is happening
-
University of Manchester
Manchester, United Kingdom Active
Researchers
- Principal investigator: Ogungbenro, Kayode — University of Manchester
- Study coordinator: Ogungbenro, Kayode
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.